Tag: Sutro
Astellas and Sutro to Jointly Develop Immunostimulatory Antibody-Drug Conjugates (iADCs)
In a joint statement after, Astellas Pharma and Sutro Biopharma, which is based in South San Francisco, is a clinical-stage oncology company pioneering site-specific and...
Antibody-drug Conjugates: Coming of Age
Antibody-based anti-cancer therapeutics have, over the last 30+ years garnered considerable success. Antibody-drug Conjugates (ADC) are included in this revolution of these novel, highly...
Sutro Biopharma Receives Milestone Payment for Bispecific Antibody-Drug Conjugate from Merck
South San Francisco-based clinical-stage biotechnology company Sutro Biopharma has received a milestone payment under its collaboration and license agreement with the healthcare division of...
The 7th Annual World ADC Awards Winners – What’s Next
The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and...
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...
Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...
Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...
Sutro Partners with The Leukemia & Lymphoma Society to Develop STRO-001
Earlier today Sutro Biopharma, a clinical-stage drug discovery, development and manufacturing company, and The Leukemia & Lymphoma Society®, the world's largest voluntary health agency...
First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...
Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...
Sutro BioPharma and Celgene Refocus Immuno-Oncology Collaboration – Rapidly Advance Promising...
Earlier today Sutro Biopharma and Celgene confirmed that the companies decided to refocusing the 2014 immuno-oncology collaboration with on four programs that are advancing...
Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival
STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...
